LIfT’s CEO Alex Blyth detailed how Immuno-Modulatory Alpha Neutrophils (IMANs) outperform traditional neutrophils by rapidly infiltrating tumours and recruiting additional immune cells.
IMANs first release chemoattractants such as CXCL10 to recruit immune cells deep inside the tumour and then through expression of co-stimulatory receptor ligands, they activate T cells, NK cells and other immune cells within the tumour microenvironment.
This novel mechanism of action (MoA) has attracted great interest for use alongside other cell therapies, antibody-dependent cell cytotoxicity (ADCC) monoclonal antibodies (MAbs), checkpoint inhibitors (CPIs) and engagers and has led to multiple collaborations.